Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 16/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968360 | 0.90 | SMO (0.38) | SMO | |
| SCHEMBL9933504 | 0.90 | KDM4E (0.41) | SMOKDM4ENPC1RAB9A | |
| SCHEMBL9933103 | 0.85 | ACVR1 (0.43) | SMO | |
| SCHEMBL9968379 | 0.84 | SMO (0.40) | SMOKDM4E | |
| SCHEMBL9932916 | 0.84 | SMO (0.40) | SMOKDM4ENPC1RAB9A | |
| SCHEMBL9932735 | 0.83 | SMO (0.49) | OPRM1OPRD1OPRK1OGFRL1SMO | |
| SCHEMBL9931663 | 0.83 | KDM4E (0.42) | OPRM1OPRD1OPRK1OGFRL1SMO | |
| SCHEMBL9968366 | 0.83 | SMO (0.39) | SMOKDM4ENPC1RAB9A | |
| SCHEMBL9933101 | 0.81 | CYP2D6 (0.45) | SMOKDM4ENPC1RAB9A | |
| SCHEMBL9968324 | 0.80 | MEN1 (0.44) | SMOKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | OPRM1 4174/4885OPRD1 3216/4885OPRK1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.